The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
| 2 | H01 | Pituitary and hypothalamic hormones and analogues | |
| 3 | H01A | Anterior pituitary lobe hormones and analogues | |
| 4 | H01AC | Somatropin and somatropin agonists | |
| 5 | H01AC06 | Tesamorelin |
| Active Ingredient | Description | |
|---|---|---|
| Tesamorelin |
Tesamorelin is indicated for the treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients with lipodystrophy. In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF, and subsequently increases IGF-1 and IGFBP-3 levels. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EGRIFTA Powder for solution fot injection | Health Products and Food Branch (CA) | MPI, CA: SPM | |
| EGRIFTA SV Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
